Shamala Balan1, Mohamed Azmi Ahmad Hassali2, Vivienne S L Mak3. 1. Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, University Sains Malaysia, 11800, Gelugor, Penang, Malaysia. shamala.balan@gmail.com. 2. Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, University Sains Malaysia, 11800, Gelugor, Penang, Malaysia. 3. Center for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia.
Abstract
BACKGROUND: In the past two decades, many legislative and regulatory initiatives were taken globally to improve drug use in children. However, children are still found to be prescribed with off-label drugs. This study was conducted to provide an overview of the worldwide trend in off-label prescribing in children from the year 1996 to 2016. DATA SOURCES: The articles published in PubMed, MEDLINE and Google Scholar were searched using text words: off-label, unlicensed, paediatric and children. Additional articles were identified by reviewing the bibliography of the retrieved articles. Full-text articles published in English which reported on the prevalence of off-label prescribing in children between January 1996 and December 2016 were included. RESULTS: A total of 101 studies met the inclusion criteria. Off-label prescribing definition included four main categories: age, indication, dose and route of administration. The three most common reference sources used in the studies were summary of product characteristics, national formularies and package inserts. Overall, the off-label prescribing rates in children ranged from 1.2 to 99.7%. The most common category of off-label prescribing in children was dose and age. CONCLUSIONS: This review highlighted that off-label prescribing in children was found to be highly prevalent throughout the past two decades, persistently in the neonatal intensive care units. This suggests that besides legislative and regulatory initiatives, behavioural, knowledge aspects and efforts to integrate evidence into practice related to off-label prescribing also need to be evaluated and consolidated as part of the concerted efforts to narrow the gaps in prescribing for children.
BACKGROUND: In the past two decades, many legislative and regulatory initiatives were taken globally to improve drug use in children. However, children are still found to be prescribed with off-label drugs. This study was conducted to provide an overview of the worldwide trend in off-label prescribing in children from the year 1996 to 2016. DATA SOURCES: The articles published in PubMed, MEDLINE and Google Scholar were searched using text words: off-label, unlicensed, paediatric and children. Additional articles were identified by reviewing the bibliography of the retrieved articles. Full-text articles published in English which reported on the prevalence of off-label prescribing in children between January 1996 and December 2016 were included. RESULTS: A total of 101 studies met the inclusion criteria. Off-label prescribing definition included four main categories: age, indication, dose and route of administration. The three most common reference sources used in the studies were summary of product characteristics, national formularies and package inserts. Overall, the off-label prescribing rates in children ranged from 1.2 to 99.7%. The most common category of off-label prescribing in children was dose and age. CONCLUSIONS: This review highlighted that off-label prescribing in children was found to be highly prevalent throughout the past two decades, persistently in the neonatal intensive care units. This suggests that besides legislative and regulatory initiatives, behavioural, knowledge aspects and efforts to integrate evidence into practice related to off-label prescribing also need to be evaluated and consolidated as part of the concerted efforts to narrow the gaps in prescribing for children.
Authors: Dermot R Doherty; Elena Pascuet; Andy Ni; Paul Stewart; William Splinter; Régis Vaillancourt Journal: Can J Anaesth Date: 2010-10-07 Impact factor: 5.063
Authors: Paulo R A Carvalho; Clarissa G Carvalho; Patrícia T Alievi; Jaqueline Martinbiancho; Eliana A Trotta Journal: J Pediatr (Rio J) Date: 2003 Sep-Oct Impact factor: 2.197
Authors: Jana Schweigertova; Alena Durisova; Dana Dolnikova; Elena Ondriasova; Martina Balazova; Veronika Slezakova; Magdalena Kuzelova Journal: Pediatr Int Date: 2015-12-16 Impact factor: 1.524
Authors: Petra Czarniak; Lewis Bint; Laurent Favié; Richard Parsons; Jeff Hughes; Bruce Sunderland Journal: PLoS One Date: 2015-03-10 Impact factor: 3.240
Authors: Irin Tanaudommongkon; Shogo John Miyagi; Dionna J Green; Janelle M Burnham; John N van den Anker; Kyunghun Park; Johanna Wu; Susan K McCune; Lynne Yao; Gilbert J Burckart Journal: Clin Pharmacol Ther Date: 2020-06-22 Impact factor: 6.875
Authors: Thaciana Dos Santos Alcântara; Fernando Castro de Araújo Neto; Helena Ferreira Lima; Dyego Carlos S Anacleto de Araújo; Júlia Mirão Sanchez; Giulyane Targino Aires-Moreno; Carina de Carvalho Silvestre; Divaldo P de Lyra Junior Journal: Int J Clin Pharm Date: 2020-11-11